Mohammad Dalabih, MD
Pulmonary Disease · Greenwood Village, CONPI 1548492788
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Actelion Pharmaceuticals US, Inc. accounts for 69.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $1,115 and has fallen 80.0% since, to $223 in 2025.
Across 42 payments — averaging $71.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$2K
- United Therapeutics Corporation$551
- Inari Medical, Inc.$215
- Merck$120
- AstraZeneca$18
Across 22 payments — averaging $4839.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$106K
What the payments were for
- Food & beverage$2,90097%
- Education$1023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 24 | $2,098 |
| United Therapeutics Corporation | 15 | $551 |
| Inari Medical, Inc. | 1 | $215 |
| Merck | 1 | $120 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$1,214
- OPSUMIT$1,214
- TYVASO$225
- REMODULIN$225
- FLOWTRIEVER CATHETER, S$215
- CT THROMBECTOMY SYSTEM KIT$215
- WINREVAIR$120
- ORENITRAM$120
- BOSENTAN$107
How this compares
$3,003 in reported general payments places this provider in the 70th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tadalafil | 25 | $20,611 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $250 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Greenwood Village
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- David SchwartzAurora$471K
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Joshiah GordonPueblo$208K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
- Charles DaleyDenver$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.